The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 6, 2007, Pages 297-306

  Menon, R M ^a   Tolbert, D ^a   Cefali, E ^a  

^a Kos Pharmaceuticals Inc   (United States)

Author keywords

Advicor; Interaction; Lovastatin; Niacin; Pharmacokinetics

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; N METHYLNICOTINAMIDE; NICOTINIC ACID; NICOTINURIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; FLUSHING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MONOTHERAPY; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; URINALYSIS; VOLUNTEER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; FEMALE; FLUSHING; HUMANS; LOVASTATIN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NIACIN; NIACINAMIDE; NICOTINIC ACIDS; PYRIDONES; TABLETS; TIME FACTORS; VITAMIN B COMPLEX;

EID: 34548755161     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.555     Document Type: Article

References (19)

1. Mevacor prescribing information, Merck and Co., November 2005.
2. Niaspan prescribing information, Kos Pharmaceuticals Inc., 2005.
3. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672-678.
4. Hunninghake DB, McGovern ME, Koren M, et al. A dose-ranging study of a new, once-daily, dual-camponent drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003; 26: 112-118.
5. Bays HE, Dujovne CA, McGovern ME, et al. Advicor Versus other Cholesterol-Modulating Agents Trial Evaluation. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003; 91: 667-672.
6. Advicor prescribing Information, Kos Pharmaceuticals Inc., 2006.
7. Fumagalli R. Pharmacokinetics of nicotinic acid and some of its derivatives. In Metabolic Effects of Nicotinic Acid and its Derivatives, Gey KF, Carlson LA (eds). Hans Huber Publishers: Bern; 1971; 33-49.
8. Carlson LA, Hanngren A. Initial distribution in mice of H3-labeled nicotinic acid studied with autoradiography. Life Sci 1964; 3: 867-871.
9. Mrochek JE. Metabolic responses of humans to ingestion of nicotinic acid and nicotinamide. Clin Chem 1976; 22: 1821-1827.
10. Ding RW, Kolbe K, Merz B, Vries JD, Weber E, Benet ZB. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 1989; 46: 642-647.
11. Felsted R, Chaykin S. N-Methylnicotinamide oxidation in a number of mammals. J Biol Chem 1967; 242: 1274-1279.
12. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97: 27C-31C.
13. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 357-364.
14. Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2003; 25: 457-481.
15. Gaudineau C, Auclair K. Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem Biophys Res Commun 2004; 317: 950-956.
16. Shibata K. Simultaneous measurement of nicotinic acid and its major metabolite, nicotinuric acid, in blood and urine by reversed-phase high performance liquid chromatography. Agric Biol Chem 1988; 52: 2973-2976.
17. Hengen N, Seiberth V, Hengen M. High-performance liquid-chromatographic determination of free nicotinic acid and its metabolite, nicotinuric acid, in plasma and urine. Clin Chem 1978; 24: 1740-1743.
18. Carter EG. Quantitation of urinary niacin metabolites by reversed-phase liquid chromatography. Am J Clin Nutr 1982; 36: 926-930.
19. Shibata K. Simultaneous micro-determination of nicotinamide and its major metabolites, N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-3-carboxamide, by high-performance liquid chromatography. J Chromatogr 1988; 425: 22-28.